A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis

Cancer

Volumn 83, Issue 5, 1998, Pages 1022-1032

  Sorbe, Bengt G ^a   Berglind, Anne Marie ^a   Andersson, Håkan ^b   Boman, Karin ^c   Högberg, Thomas ^d   Hallgren, Monica ^d   Schmidt, Margareta ^e  

^a ÖREBRO MEDICAL CENTRE HOSPITAL   (Sweden)

^b Law University of Gothenburg   (Sweden)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

5 HT3 receptor antagonists; Antiemetics; Chemotherapy; Delayed emesis; Dexamethasone; Tropisetron

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; PACLITAXEL; PLACEBO; PLATINUM DERIVATIVE; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; TENIPOSIDE; TROPISETRON; VINCRISTINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MIXTURE; DRUG TOLERABILITY; FEMALE; GYNECOLOGIC CANCER; HEADACHE; HUMAN; INSOMNIA; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; VERTIGO; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; INDOLES; MIDDLE AGED; NAUSEA; SEROTONIN ANTAGONISTS; TIME FACTORS; VOMITING;

EID: 0032167779     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980901)83:5<1022::AID-CNCR29>3.0.CO;2-8     Document Type: Article

References (30)

1. Coates A, Abraham S, Kaye SB, Sowerbutte T, Frewin C, Fox RM, et al. On the receiving end-patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983;19:203-8.
2. Kris MG, Gralla RJ, Clark RA, Tyson LB, O'Connell JP, Wertheim MS, et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985;3:1379-84.
3. Gralla RJ, Itri LM, Pisko SE, Anna E, Squillante RN, Kelsen DP, et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 1981;305:905-9.
4. Andrews PLR, Davis CJ, Bingham S, Davidson HIM, Hawthorn J, Maskell L. The abdominal visceral innervation and the emetic reflex: pathways, pharmacology, and plasticity. Can J Physiol Pharmacol 1990;68:325-45.
5. Cubeddu LX, Hoffman IS, Fuenmayor NT, Finn AL. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens. J Clin Oncol 1990;8:1721-7.
6. Kaizer L, Warr D, Hoskins P, Latreille J, Lofters W, Yau J, et al. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994;12:1050-7.
7. Kris MG, Gralla RJ, Tyson LB, Clark RA, Cirrincione C, Groshen S. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989;7:108-14.
8. De Mulder PHM, Seynaeve C, Vermorken JB, van Liessum PA, Mols-Jevdevic S, Allman EL, et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 1990;113:834-40.
9. Johnston D, Latreille J, Laberge F, Stewart D, Rusthoven J, Findlay B, et al. Preventing nausea and vomiting during days 2-7 following high dose cisplatin chemotherapy. A study by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) [abstract 17451. Proc Am Soc Clin Oncol 1995;14:529.
10. Leibundgut U, Lancranjan I. First results with ICS 205-930 (5-HT3 receptor antagonist) in prevention of chemotherapy-induced emesis. Lancet 1987;I:1198.
11. Sorbe B, Högberg T, Glimelius B, Schmidt M, Wernstedt L, Hansen O, et al. A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. Cancer 1994;73:445-54.
12. Sorbe B, Högberg T, Himmelmann A, Schmidt M, Räisänen I, Stockmeyer M, et al. Efficacy and tolerability of tropisetron in comparison with a combination of tropisetron and dexamethasone in the control of nausea and vomiting induced by cisplatin-containing chemotherapy. Eur J Cancer 1994;30A:629-34.
13. Kris MG, Pisters KMW, Hinkley L. Delayed emesis following anticancer chemotherapy. Support Care Cancer 1994;2:297-300.
14. Olver I, Paska W, Depierre A, Seitz JF, Stewart DJ, Goedhals L, et al. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ann Oncol 1996;7:945-52.
15. Smyth J. Delayed emesis after high-dose cisplatin: the residual problem. Presented at Proceedings of the European Society of Medical Oncology, Lyon, France, November 8, 1992.
16. Jones AL, Hill AS, Soukop M, Hutcheon AW, Cassidy J, Kaye SB, et al. Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 1991;338:483-7.
17. Beck TM. The pattern of emesis following high-dose cyclophosphamide and antiemetic efficacy of ondansetron. Anticancer Drugs 1995;6:237-42.
18. Roila F, Ballatori E, de Angelis V, Tonato M, Riva E, Panza MT, et al. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995;332:1-5.
19. Sorbe B, Andersson H, Schmidt M, Söderberg M, Högberg T, Wernstedt L, et al. Tropisetron (Navoban) in the prevention of chemotherapy-induced nausea and vomiting: the Nordic experience. Support Care Cancer 1994;2(6):393-9.
20. Florczyk AP, Schurig JE, Bradner WT. Cisplatin-induced emesis in the ferret: a new animal model. Cancer Treat Rep 1982;66:187-9.
21. Rudd JA, Jordan CC, Naylor RJ. Profiles of emetic action of cisplatin in the ferret: a potential model of acute and delayed emesis. Eur J Pharmacol 1994;262:R1-2.
22. Grélot L, Stunff HL, Milano S, Blower PR, Romain D. Repeated administration of the 5-HT3 receptor antagonist granisetron reduces the incidence of delayed cisplatin-induced emesis in the piglet. J Pharmacol Exp Ther 1996;279: 255-61.
23. Milano S, Blower P, Romain D, Grélot L. The piglet as a suitable animal model for studying the delayed phase of cisplatin-induced emesis. J Pharmacol Exp Ther 1995;274: 951-61.
24. Navari RM, Madajewicz S, Anderson N, Tchekmedyian NS, Whaley W, Garewal H, et al. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol 1995;13:2408-16.
25. Lofters WS, Pater JL, Zee B, Dempsey E, Walde D, Moquin J-P, et al. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 1998;15:2966-73.
26. Ossi M, Anderson E, Freeman A. 5-HT3 receptor antagonists in the control of cisplatin-induced delayed emesis. Oncology 1996;53:78-85.
27. Olver I, Paska W, Depierre A, Seitz JF, Stewart DJ, Goedhals L, et al. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ann Oncol 1996;7:945-52.
28. Gralla RJ, Rittenberg C, Peralta M, Lettow L, Cronin M. Cisplatin and emesis: aspects of treatment and a new trial for delayed emesis using oral dexamethasone plus ondansetron beginning at 16 hours after cisplatin. Oncology 1996; 53:86-91.
29. Rudd JA, Jordan CC, Naylor RJ. The action of the NK1 tachykinin receptor antagonist , CP 99,994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret. Br] Pharmacol 1996;119:931-6.
30. Kris MG, Radford JE, Pizzo BA, Inabinet R, Hesketh A, Hesketh PJ. Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin. J Natl Cancer Inst 1997;89: 817-8.